Molecular Partners Selects MP0730 As Lead CD70-Targeting Radio-DARPin For Targeted Alpha Therapy In Kidney Cancer, Third Radiotherapeutics Program; First-In-Human Expected 2027
Share
Why It Matters
Molecular Partners picked a new cancer medicine to test in people. This shows the company is growing its treatment programs and moving forward.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.